Sandoz, the generics division of Novartis, announced on 13 February 2018 the approval of its 40 mg follow-on version of glatiramer acetate by the US Food and Drug Administration (FDA).
- Home
-
Generics
News
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP
Research
- Re-evaluation of the use of generics, especially when treating conditions such as epilepsy
- Repurposing generic drugs can save time and money
- Availability of medicines and the sustainable development of the national health system in Russia
- Generic etoricoxib is equivalent to the reference drug
-
Biosimilars
News
- New adalimumab biosimilars prepare to launch in Canada, US and Europe
- FDA approves Amneal’s bevacizumab biosimilar
- Europe: positive opinion for Inpremzia and Truvelog Mix 30 and Stimufend authorized
- FDA approves Kashiv Biosciences’ filgrastim biosimilar
Research
- Innovent and Eli Lilly announce final results for sintilimab plus biosimilar bevacizumab injection
- Biosimilar adoption and prescribing in Japan: a physician opinion survey
- Totality of evidence supporting approval of Avsola in the treatment of IBD
- Survey results of biosimilars use among Spanish physicians and pharmacists
- MORE EDITORIAL SECTIONS
- Search
Post your comment